期刊
IMMUNOTHERAPY
卷 13, 期 3, 页码 257-270出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0179
关键词
advanced cancer; bias; immortal time; immune checkpoint; immunotherapy; IrAE; landmark; response; survival; toxicity
类别
A minority of studies did not account for immortal time bias and showed conflicting results. It was found that IrAEs in patients were significantly associated with outcomes, although the effect size was smaller in comparison.
Only a minority of studies addressing the association between immune-related adverse events (IrAE) and outcome considered the immortal time bias, with conflicting results. PubMed, Embase, Web of Science and Scopus were searched through 2 January 2020. Studies reporting the impact of IrAE on outcome in patients treated with antiprogrammed death receptor 1 or PD-L1 were included. Twenty nine articles were included. IrAEs were associated with improved outcomes with high heterogeneity. With a landmark approach, the association between IrAE and outcome remains significant but the effect size was smaller (hazard ratio 0.61 vs 0.41 for overall survival; p = 0.015; hazard ratio 0.66 vs 0.47 for progression-free survival, p = 0.029; odds ratio 2.59 vs 6.77 for overall response rate; p < 0.001), no significant heterogeneity. Our analysis suggests a confounding effect of immortal time bias and a real effect of IrAE on outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据